Key result
The SEMI-CI study recruited 867 patients with STEMI in Isfahan, Iran, reporting an in-hospital mortality rate of 8.3% and establishing a cohort for 5-year cardiovascular follow-up.
Why the study?
Cardiovascular disease is a leading cause of mortality and morbidity in Iran, highlighting the need to evaluate clinical characteristics, management, and 5-year outcomes in acute myocardial infarction.
Cohort (n=867)
No
The SEMI-CI study establishes a 5-year longitudinal cohort of 867 STEMI patients in Iran to evaluate secondary prevention adherence and long-term cardiovascular outcomes.
BACKGROUND: Cardiovascular disease (CVD) is one of the most important causes of mortality and morbidity in Iran. Secondary prevention of acute myocardial infarction (AMI) is necessary. The main aim of this cohort is evaluating clinical, paraclinical, management, and 5-year major events of the participants in Isfahan, Iran. METHODS: All consecutive patients with AMI hospitalized in Chamran Hospital, Isfahan, during 1 year from march 2015 were recruited and followed for 5 years. ST-Elevation Myocardial Infarction Cohort Study (SEMI-CI) has been initiated as a longitudinal study to evaluate course of patients with AMI in Iran, adherence to evidence-based secondary prevention drug, and five-year events such as death, re-myocardial infarction (REMI), re-hospitalization, congestive heart failure (CHF), and referring to another procedure [percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), and resynchronization therapy]. RESULTS: A total of 867 patients with ST-elevation myocardial infarction (STEMI) with mean age of 60.91 ± 12.76 years were recruited. 705 (81.3%) subjects were men with mean age of 59.63 ± 12.59 years. 470 (54.2%) patients had anterior AMI (ant-AMI) and the rest had other types of AMI. The ejection fraction (EF) mean was 37.80 ± 11.74 percent. A total of 30 (3.5%) cases of AMI had not received reperfusion. 445 (51.4%) had primary PCI and 392 (45.2%) had thrombolysis at first revascularization strategy. In-hospital death occurred in 72 participants (8.3%). Drug during hospital included: at discharge, 767 (88.5%) received aspirin, 787 (90.7%) statin, 697 (80.4%) beta-blocker, and 480 (55.4%) angiotensin-converting enzyme (ACE) inhibitor. CONCLUSION: According to the best of our knowledge, it is among few cohorts in Eastern Mediterranean Region (EMR) in patients with AMI. This paper showed methodology of this study in patients with STEMI and its follow-up protocol. We can use this result in policy-making for improving secondary prevention strategies.
No takes yet. Share an insight, caveat, or question.
Sadeghi et al. (2021) conducted a cohort in ST-elevation myocardial infarction (n=867). ST-elevation myocardial infarction was evaluated on In-hospital death. The SEMI-CI study recruited 867 patients with STEMI in Isfahan, Iran, reporting an in-hospital mortality rate of 8.3% and establishing a cohort for 5-year cardiovascular follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: